<unk>  is the International Nonproprietary Name of a short-acting SSRI drug currently being considered for approval by the Food and Drug Administration (FDA) for the treatment of premature ejaculation in men, which would make it the first drug approved for such treatment.  It is currently in Phase III of the approval process.
Dapoxetine
Atomoxetine
Duloxetine
Vortioxetine
Fluoxetine
Nabilone
Guanfacine
Norfluoxetine